David N. Gill

David N. Gill has over 30 years of experience in senior operating and financial roles in the life sciences industry. Mr. Gill currently serves as Chief Financial Officer of Perspectum Ltd., a UK-based diagnostic tools company. He was previously the President and Chief Financial Officer of EndoChoice Holdings, Inc., a publicly traded medical device company focused on gastroenterology products that were acquired in November 2016. Prior to EndoChoice, he was the Chief Financial Officer of INC Research from 2011 to 2013 after having served as an independent board member from 2007 through 2010. INC Research (now known as Syneos) is a large, global clinical research organization (CRO) that provides outsourced pharmaceutical development services on a global basis. Earlier in his career, Mr. Gill served in a variety of senior executive leadership roles for several medical device companies, including TransEnterix, NxStage Medical, CTI Molecular Imaging, Inc., Novoste Corporation, and Dornier Medical Systems. He currently also serves as a director of the following public companies: Evolus, Inc. and Strongbridge Biopharma plc.